GGrantIndex
Sort

15,842 grants matching pancreatic cancer

A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer

$430,565
Julie R Palmer · Boston University Medical Campus · U01 · FY2018 · CA

Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer

$430,481
Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

VEGF and PDGF in angiogenesis and tumor progression

$430,440
David A Cheresh · University Of California, San Diego · R37 · FY2013 · CA

Immune cell control of ovarian cancer

$430,385
Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Role of nonsense mediated RNA decay in pancreatic cancer

$430,352
Mark Reid Philips · New York University School Of Medicine · R01 · FY2019 · CA

Regulation Of Immune Responses In Humans and in Experimental Animals

$430,295
Warren Strober · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI

Prevention of Type 1 Diabetes with MMP Inhibitors

$430,224
City Of Hope/Beckman Research Institute · R21 · FY2002 · DK

Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy

$430,212
Edgar G. Engleman · Stanford University · P01 · FY2025 · CA

Mechanisms of diabetic amyloid formation via 2D IR spectroscopy

$430,078
Martin T Zanni · University Of Wisconsin-Madison · R01 · FY2020 · DK

Chemotherapy plus vaccine for metastatic breast cancer

$429,983
Johns Hopkins University · R01 · FY2004 · CA

Measuring and Modulating Oxidative DNA Damage Surveillance Pathways

$429,953
Eric T. Kool · Stanford University · R01 · FY2017 · CA

Reprogramming the pancreatic tumor microenvironment with immunotherapy

$429,841
Lei Zheng · Johns Hopkins University · R01 · FY2017 · CA

Novel Inhibitors of Akt Signaling in Pancreatic Cancer

$429,731
Garth Powis · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA

PRSS1 Mutation and Pancreatic Cancer Tumorigenesis

$429,661
Baoan Ji · Mayo Clinic Jacksonville · R01 · FY2022 · CA

Project 2: Combined CAR-T cell therapy

$429,640
Gianpietro Dotti · Univ Of North Carolina Chapel Hill · P50 · FY2024 · CA

Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes

$429,528
Stephen J Pandol · Cedars-Sinai Medical Center · U01 · FY2019 · DK

Drug Mechanism of Action-based targeting of tumor subpopulations

$429,473
Andrea Califano · Columbia University Health Sciences · U54 · FY2024 · CA

Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium

$429,377
Robert M Straubinger · State University Of New York At Buffalo · R01 · FY2017 · CA

Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium

$429,377
Robert M Straubinger · State University Of New York At Buffalo · R01 · FY2016 · CA

Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium

$429,377
Robert M Straubinger · State University Of New York At Buffalo · R01 · FY2018 · CA

The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

$429,300
Suresh T. Chari · Mayo Clinic Rochester · U01 · FY2017 · DK

The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

$429,300
Suresh T. Chari · Mayo Clinic Rochester · U01 · FY2018 · DK

The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

$429,300
Suresh T. Chari · Mayo Clinic Rochester · U01 · FY2016 · DK

Molecular Magnetic Resonance Imaging of Inflammation

$429,230
Eric Michael Gale · Massachusetts General Hospital · R01 · FY2021 · DK

Molecular Magnetic Resonance Imaging of Inflammation

$429,230
Eric Michael Gale · Massachusetts General Hospital · R01 · FY2022 · DK